KIT and lung carcinoma: For example, dysregulation of c-Kit/SCF signaling and gain-of-function c-Kit mutations have been implicated in different cancers [23,24,25,26,27,28], including thyroid carcinoma, oncocytic intraductal papillary mucinous neoplasms (IPMNs) of the pancreas, and lung cancer [29,30,31].